Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommended Phase 2 dose (RP2D) showed an overall response rate (ORR) of 70 percent, with 60 percent of patients achieving a very good partial response (VGPR) or better among those who had received a median of six prior lines of therapy.[4] The median time to first confirmed response was one month (range, 0.2–3.8 months).4 These data will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation on Tuesday, June 8 (Abstract #8008).4 “Most patients diagnosed with multiple myeloma will relapse over the course of their disease. Patients in this study had progressed, had relapsed after, or were refractory to numerous multiple myeloma therapies. There is a significant need for new treatments for multiple myeloma,” said Jesus G. Berdeja, M.D., Director of Myeloma Research Sarah Cannon Research Institute...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

During her career, Debbie DiCarlo had worked for nonprofits dealing with immigration, foster case, sex trafficking and domestic violence, but she never saw herself working for a cancer organization. That is, until her best friend was diagnosed with cancer, and she subsequently moved to the Valley from California to do just that.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
One new case in Queensland as Melbourne CBD turned into no-go zone and police prepare to disrupt protest planned in SydneyNew Doherty modelling advises ‘medium’ Covid restrictions until 80% vaccination target reachedYouth corrections officer dies from CovidCovid vaccine rollout and rates tracker; Cases, trends and data trackerGet our free news app;get our morning email briefing2.05amBSTNSW isn ’t hosting a press conference today.Instead NSW Health ’sJeremy McAnulty is providing an update via NSW Health ’s Facebook page. You can watchhere.2.02amBSTNSW has recorded 1,331 new locally acquired cas...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus Australia news Infectious diseases Science Medical research Source Type: news
During her career, Debbie DiCarlo had worked for nonprofits dealing with immigration, foster case, sex trafficking and domestic violence, but she never saw herself working for a cancer organization. That is, until her best friend was diagnosed with cancer, and she subsequently moved to the Valley from California to do just that.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Hi, just started a practice at a hospital and much of what I'm seeing is Fibromyalgia + Opiates that other clinics do not want. My goal is to ramp up (as I'm setting 4-5 patients a day) with plans to build a more interventional practice. What advice do you have to try and achieve this?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighti...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very high...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anemia | Brain | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Health Management | Heart | Hematology | Hypertension | Infectious Diseases | Learning | Legislation | Leukemia | Myeloma | Neurology | Neuroscience | Oral Cancer | Orthopaedics | Pain | Pharmaceuticals | Pulmonary Hypertension | Science | Skin | Statistics | Study | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines